Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of glycolytic pathway key enzyme in infantile hemangioma

An infantile hemangioma and key enzyme technology, which is applied in the application field of glycolysis pathway key enzymes in infantile hemangioma, and can solve the problems of non-specificity and poor curative effect.

Pending Publication Date: 2022-03-25
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the traditional sense, targeting tumor drivers such as vascular endothelial growth factor (VEGF) and other growth factors to treat tumors is effective at the beginning, but the long-term efficacy is poor because it is not specific. sex

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glycolytic pathway key enzyme in infantile hemangioma
  • Application of glycolytic pathway key enzyme in infantile hemangioma
  • Application of glycolytic pathway key enzyme in infantile hemangioma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Inhibition of HemEC proliferation

[0054] The ability of PFK15 to kill HemEC or inhibit the proliferation of HemEC was measured as follows: 24h after PFK15 acted on HemEC, it was detected by CCK8 method. The effect of HemEC being inhibited by PFK15 is as follows: Figure 4A As shown, different concentrations of PFK15 have different inhibitory effects on HemEC, and with the increase of PFK15 concentration, the inhibitory effect on HemEC gradually increases.

[0055] Desired cells are HemEC, containing 8 x 10 in a culture volume of 100 per well 3 Seed in 96 wells. After 24 hours, the cell culture medium was replaced, and the drug was diluted to the desired concentration, mixed in 100 μl medium and added to a 96-well plate to continue interfering with the cells for 24 hours. On the third day, the medium in the 96 wells was aspirated and washed once with PBS, and then 110 μl of CCK8 and medium mixture was added to each well (the volume ratio of CCK8 and medium was 1:10)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology, and discloses an application of a glycolytic pathway key enzyme in infantile hemangioma, the glycolytic pathway key enzyme is highly expressed in IH proliferation period tissue and hemangioma endothelial cells, and proliferation and migration of HemEC can be inhibited and apoptosis can be promoted by inhibiting the activity of the key enzyme phosphofructokinase-2 / fructose-2, 6-diphosphatase 3. The identification method comprises the following steps: carrying out immunohistochemical analysis on the expression of glycolysis key enzyme in IH proliferation stage tissue and degradation stage tissue, analyzing the expression conditions of HemEC and umbilical vein endothelial cells, and detecting the proliferation, migration and apoptosis capabilities of the HemEC after the inhibitor intervenes in PFKFB3 expression. According to the invention, the expression condition and the effect of a glycolysis pathway key enzyme in IH are determined, the pathological mechanism of IH occurrence and development is disclosed, and an experimental basis is provided for IH treatment taking glycolysis as a target spot.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the application of a key enzyme of glycolysis pathway in infant hemangioma (infantile hemangioma, IH). Background technique [0002] At present, IH is the most common benign tumor in infants and young children, with an incidence rate of about 4-5%. Previous studies have found that differential mRNAs in proliferative and extinction IH tissues are mainly enriched in signaling pathways including metabolic pathways. Studies have shown that glucose metabolism reprogramming, as one of the characteristics of tumor cells, plays an important role in the occurrence and development of various tumors, including lung cancer, breast cancer, and gastric cancer. However, related technical solutions for verifying the role of key enzymes in the glycolysis pathway in IH have not been reported in the prior art. Therefore, it is urgent to design a method that can verify the role of key enzy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/573G01N33/531G01N21/64
CPCG01N33/57407G01N33/57484G01N33/573G01N33/531G01N21/6458G01N2333/4703G01N2333/916G01N2333/904G01N2333/91215
Inventor 吉毅杨开颖邱桐张学鹏周江元陈思源龚雪兰钰茹张赓张梓欣
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com